Table 2. Distribution of Genotypes Across Study Groups.
| Genetic Loci | Warfarin Dosing, No. (%) | |
|---|---|---|
| Genotype-Guided (n = 808) |
Clinically Guided (n = 789) |
|
| CYP2C9*2 (430C>T) rs1799853 | ||
| CC | 641 (79.3) | 612 (77.6) |
| CT | 151 (18.7) | 169 (21.4) |
| TT | 16 (2.0) | 8 (1.0) |
| CYP2C9*3 (1075A>C) rs1057910 | ||
| AA | 709 (87.8) | 677 (85.8) |
| AC | 94 (11.6) | 102 (12.9) |
| CC | 5 (0.6) | 10 (1.3) |
| VKORC1*2 (-1639G>A) rs9923231 | ||
| GG | 305 (37.8) | 293 (37.1) |
| AG | 371 (45.9) | 352 (44.6) |
| AA | 132 (16.3) | 144 (18.3) |
| CYP4F2*3 (1297G>A) rs2108622 | ||
| GG | 379 (46.9) | 397 (50.3) |
| AG | 350 (43.3) | 331 (42.0) |
| AA | 79 (9.8) | 61 (7.7) |